Cascadian Therapeutics (CASC) Releases Earnings Results, Misses Expectations By $-0.14 EPS

Cascadian Therapeutics (CASC) reported quarterly earnings results on Monday, Aug-8-2016. The company reported $-0.26 earnings per share for the quarter, missing the analyst consensus estimate by $-0.14. Analysts had a consensus of $-0.12. During the same quarter in the previous year, the company posted $-0.11 EPS.

In a different news, on Jun 28, 2016, Scott Dunseth Myers (CEO) purchased 62,500 shares at $0.80 per share price.

Cascadian Therapeutics

Leave a Reply

Cascadian Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cascadian Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.